Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Post by GoldenDilemmaon Nov 09, 2016 12:57pm
136 Views
Post# 25440958

Woo!

Woo!With Trump winning and IBB handling it well, does that mean Deerfield maybe stops shorting this stock? 

Who knows - if they did have a short bias here in previous months (as I outlined in previous posts), it could have been to hedge the potential risk of Democratic scrutiny on the pharma sector. It may have also been a hedge against the entire IBB seemingly "stressed" by what Bernie and Hillary were spewing. Doesn't give much room for something to move up with that much negative sentiment.

Because, aside from us not having Q4'16/Q1'17 financials for ARLZ - the company has never been in a better position so this depreciation has been quite ludicrous.

In any case, just based on TA, the day chart for ARLZ looks great! What is key is whether these moves across the pharmaceutical sector fades in the coming days, or the sentiment remains. 

Note: no confirmation on a Deefield short... but, do consider it ;) 
<< Previous
Bullboard Posts
Next >>